Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
BioAtla ( (BCAB) ) has provided an update.
BioAtla, Inc. has entered into a securities purchase agreement with institutional investors to raise approximately $9.2 million through a registered direct offering of common stock and warrants. The proceeds will fund research and development, particularly for its mid-stage clinical programs, including BA3182 and mecbotamab vedotin, as well as support corporate operations and partnership activities. The offering, facilitated by Tungsten Advisors, underscores BioAtla’s strategic efforts to advance key clinical programs and strengthen its market positioning.
More about BioAtla
BioAtla is a global clinical-stage biotechnology company focused on developing Conditionally Active Biologic (CAB) antibody therapeutics for treating solid tumors. The company operates in San Diego, California, and Beijing, China, through its partnership with BioDuro-Sundia. BioAtla’s proprietary CAB technology aims to create more selective and effective therapeutic antibodies with lower toxicity and cost-efficient manufacturing. The company holds extensive patent protection for its CAB technology and is advancing several clinical programs, including CAB-AXL-ADC and CAB-ROR2-ADC, in Phase 2 testing.
YTD Price Performance: -51.63%
Average Trading Volume: 1,217,805
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $57.53M
For detailed information about BCAB stock, go to TipRanks’ Stock Analysis page.
